Try our beta test site
132 studies found for:    Recruiting | Cancer | United States, District of Columbia | Georgetown
Show Display Options
Rank Status Study
1 Recruiting Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: TAS-102 and Bevacizumab
2 Recruiting A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
Condition: Colon Cancer
Intervention: Drug: Regorafenib
3 Recruiting ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Intervention: Drug: ABT-888 and mFOLFOX-6
4 Recruiting Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Other: Molecularly Tailored Second Line Therapy;   Drug: Standard of Care Second Line Therapy
5 Recruiting Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Condition: Small Cell Lung Cancer ( SCLC )
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Biological: MPDL3280A
6 Recruiting Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
Conditions: Esophageal Cancer;   Gastric Cancer
Interventions: Drug: Modified FOLFOX6;   Drug: Docetaxel/Capecitabine;   Drug: Cisplatin/Irinotecan;   Drug: Cisplatin/Docetaxel;   Drug: IRI/EPI;   Drug: EPI/Docetaxel;   Drug: Irinotecan/Docetaxel;   Drug: Docetaxel
7 Recruiting A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors
Conditions: Colorectal Cancer;   Head and Neck Cancer
Intervention: Drug: Nilotinib + Cetuximab
8 Recruiting Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Conditions: EGFR Gene Mutation;   Nonsmall Cell Lung Cancer
Interventions: Drug: Dasatinib;   Drug: Osimertinib
9 Recruiting Cardiac Safety Study in Patients With HER2 + Breast Cancer
Conditions: HER2 Positive Breast Cancer;   Left Ventricular Function Systolic Dysfunction
Intervention: Drug: Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine
10 Recruiting Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
Conditions: Breast Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Other: counseling intervention;   Other: educational intervention;   Other: survey administration;   Behavioral: psychosocial assessment and care;   Behavioral: supportive care
11 Recruiting A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)
Condition: Breast Cancer
Intervention: Radiation: CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)
12 Recruiting Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
Condition: Colorectal Neoplasm
Intervention: Drug: DS-8273a + nivolumab
13 Recruiting Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies
Condition: Cancer
Intervention: Drug: PFK-158
14 Recruiting Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)
Condition: Solid Tumors That Overexpress HER2 (HER2 Positive)
Intervention: Drug: FS102
15 Recruiting A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)
Condition: Lung Cancer
Intervention: Other: VATS-associated best practices
16 Recruiting Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer
Condition: Hormone Receptor Positive HER-2 Negative Breast Cancer
Intervention: Drug: Palbociclib + Letrozole
17 Recruiting Multi-Institutional Registry for Prostate Cancer Radiosurgery
Conditions: Prostate Cancer Early Risk Treated by Radiosurgery;   Prostate Cancer Intermediate Risk Treated by Radiosurgery
Intervention:
18 Recruiting PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Standard Adjuvant Endocrine Therapy
19 Recruiting PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Condition: Colorectal Cancer
Interventions: Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
20 Recruiting HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Condition: Breast Cancer
Interventions: Drug: HKI-272;   Procedure: Surgical Resection;   Drug: Capecitabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.